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Abstract
 
Mycolic acids represent a major component of the unique cell wall of mycobacteria. Mycolic
acid biosynthesis is inhibited by isoniazid, a key frontline antitubercular drug that is inactivated
by mycobacterial and human arylamine 
 
N
 
-acetyltransferase (NAT). We show that an in-frame
deletion of 
 
Mycobacterium bovis
 
 BCG 
 
nat
 
 results in delayed entry into log phase, altered mor-
phology, altered cell wall lipid composition, and increased intracellular killing by macrophages.
In particular, deletion of 
 
nat
 
 perturbs biosynthesis of mycolic acids and their derivatives and
increases susceptibility of 
 
M. bovis
 
 BCG to antibiotics that permeate the cell wall. Phenotypic
traits are fully complemented by introduction of 
 
Mycobacterium tuberculosis nat
 
. We infer from
our findings that NAT is critical to normal mycolic acid synthesis and hence other derivative
cell wall components and represents a novel target for antituberculosis therapy. In addition, this
is the first report of an endogenous role for NAT in mycobacteria.
Key words: isoniazid • macrophage • 
 
Mycobacterium tuberculosis
 
 • cell wall • metabolism
 
Introduction
 
Mycobacterium tuberculosis
 
, the etiological agent of tuberculosis,
is responsible for two to three million deaths per year,
worldwide (1, 2). Chemotherapy is available for tuberculosis,
but requires an extremely long, complex multiple therapy
regimen to resolve infection (3). The length of this course
leads to high rates of patient noncompliance, suspected to
account for the increasing number of drug-resistant clinical
isolates of 
 
M. tuberculosis
 
 now observed (4). Additional anti-
tuberculosis drugs are now urgently required both to treat
organisms already resistant to existing therapeutics, and to
limit the emergence of drug resistance by use with current
treatment regimens to shorten the course of therapy.
 
M. tuberculosis
 
 belongs to the genus 
 
Mycobacterium
 
, char-
acterized by a unique cell wall rich in unusual glycolipids,
polysaccharides, and lipids, including mycolic acids. Bio-
synthetic pathways of cell wall components have proved to
be effective targets for several major antitubercular drugs,
including the frontline drug isoniazid (INH), which inhibits
mycolic acid biosynthesis. Mycolic acids are large, 
 
 
 
alkyl
 
 
 
hydroxy fatty acids with the general structure of R
 
1
 
-
CH(OH)-CH(R
 
2
 
)-COOH, where R
 
1 
 
is a meromycolate
chain typically containing 50–56 carbons and R
 
2 
 
is a shorter
 
 
 
branch containing 22–26 carbons. They constitute the
inner leaflet of the lipid bilayer of the mycobacterial cell
wall and form an effective barrier to the penetration of anti-
biotics and chemotherapeutic agents (5). The effect of INH
on cell wall and mycolic acid synthesis is long established
(6–13), although there has been controversy over the mo-
lecular targets of INH. We recently reported arylamine
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N
 
-acetyltransferase (NAT) of 
 
M. tuberculosis
 
 is a modifier of
INH involved in mediating INH resistance (14,15).
Genes encoding NAT are present in a range of bacterial
genomes (15, 16). This observation first provoked intrigue
because human NATs have long been identified as drug
metabolizing enzymes (17). NAT represents one of the first
examples of pharmacogenetic variation and its study re-
vealed the role of acetyl-CoA as an acetyl donor. In particu-
lar, NAT2 in humans is known to be responsible for the in-
activation of INH through acetylation (18–20). We have
studied mycobacterial NATs in this laboratory as potential
contributors to the variation in INH resistance among 
 
M.
tuberculosis
 
 clinical isolates. It is now known that 
 
nat
 
 in 
 
M.
tuberculosis
 
 is polymorphic (14). The expression product
acetylates and inactivates INH in vitro, and it has been sug-
gested that this activity and polymorphism might be a con-
tributory factor to INH resistance (14, 15, 21). We know
that 
 
nat
 
 is expressed in 
 
M. tuberculosis
 
 and 
 
Mycobacterium bovis
 
BCG and the gene product is active (14). The genomes of
 
M. tuberculosis 
 
(22) and 
 
M. bovis 
 
(23) have been sequenced.
 
M. bovis
 
 is a member of the 
 
M. tuberculosis
 
 complex. 
 
M. bovis
 
BCG is an attenuated 
 
M. bovis
 
 strain in use as a vaccine. The
 
nat
 
 gene is maintained in 
 
M. bovis
 
 BCG and is identical in
sequence to that of 
 
M. tuberculosis 
 
(14–16, 22, 23).
An endogenous role for the 
 
N
 
-acetylation activity of
NAT has not been reported for any mycobacterial species
and to this end we have generated an in-frame deletion of
 
nat
 
 in 
 
M. bovis
 
 BCG. We examined the growth, cell mor-
phology, and extractable cell wall lipid composition of the
resulting knockout strain. The most important finding is
that NAT is essential for normal mycolic acid synthesis in
 
M. bovis
 
 BCG, suggesting that mycolic acid biosynthesis in-
volves an as yet unidentified pathway involving NAT. In
addition, loss of NAT activity resulted in increased intracel-
lular killing of 
 
M. bovis
 
 BCG by macrophages. We were
able to restore 
 
M. bovis
 
 BCG wild-type phenotype via func-
tional complementation with 
 
M. tuberculosis
 
 
 
nat
 
, indicating
that NAT has an endogenous role within mycobacteria. We
propose that NAT, with its crucial role in mycolic acid bio-
synthesis, represents a novel antituberculosis drug target.
 
Materials and Methods
 
Bacterial Strains and Culture Conditions. M. bovis
 
 BCG Pasteur
and genetically modified strains, including the 
 

 
nat
 
 complemented
with 
 
nat
 
 in pACE1 (24), were cultured at 37
 

 
C in roller bottles
with rotation at two revolutions per minute in Middlebrook 7H9
liquid medium containing 10% (vol/vol) albumin-dextrose-catalase
(ADC; Difco) and 0.05% (vol/vol) Tween 80 (Sigma-Aldrich), and
on Middlebrook 7H10 agar plus 10% (vol/vol) oleic acid–ADC
(OADC; Difco), unless otherwise stated. Cultures were harvested
from log phase at an OD
 
600 
 
of 0.6–1.2. NAT activity in cell lysates
was determined after HPLC analysis as previously described (14).
 
Generation of nat Knockout. M. bovis
 
 BCG Pasteur with an in-
frame unmarked deletion of the 
 
nat
 
 open reading frame (ORF)
was generated by homologous recombination, using plasmids and
methods previously described (24, 25). The suicide construct com-
prised p2NIL, homology arms of 
 

 
1 Kb flanking the 
 
M. bovis
 
 BCG
 
nat
 
 ORF, and a selectable marker cassette from pGOAL19. Prepa-
ration and transformation of 
 
M. bovis
 
 BCG electrocompetent cells
and selection of the knockout strain were performed exactly as
described (25). For the resultant strain, the 
 
nat
 
 ORF (Rv3566c)
and the five upstream ORFs (Rv3566A, Rv3567c, Rv3568c,
Rv3569c, and Rv3570c) in the putative 
 
nat
 
 operon (16) were am-
plified using pFU DNA polymerase (Promega) with gene-specific
primers (Rv3566c 
 
nat
 
: 5
 

 
-GAC GAG GTC AGA ATG GCA AC-
3
 
 
 
and 5
 

 
-GGG GTT CGT TTG TTC GGA TA-3
 

 
; Rv3566A:
5
 

 
-GTGTCCGGCGCCGAT-3
 
 
 
and 5
 

 
-TCAGATCCAGTGC-
CATGTTGC-3
 

 
; Rv3567c: 5
 

 
-ATGTCGGCTCAGATCGA-
TCC-3
 
 
 
and 5
 

 
-CTAGAGCCAGGTGTCCTGG-3
 

 
; Rv3568c:
5
 

 
-TGAGCATCCGGTCGCTG-3
 
 
 
and 5
 

 
-CTAGCCGCGAG-
CGCCTAC-3
 

 
; Rv3569c: 5
 

 
-ATGACAGCTACCGAGGAA-
TTG-3
 
 
 
and 5
 

 
-TCATCTGCCACCTCCCAG-3
 

 
; Rv3570c:
5
 

 
-GTGACGTCCCATTCAACAGCG-3
 
 
 
and 5
 

 
-TAGACCAT-
GGTGTCGCCG-3
 

 
). DMSO at 6% (vol/vol) was added to all
reactions. Mycobacterial cells were denatured at 95
 

 
C for 10 min
as an extra cycle before the addition of the enzyme mix. The
PCR cycle was repeated 30 times. The DNA sequences of
the PCR products were confirmed by automated sequencing
(Biochemistry Department, DNA Sequencing Facility, Oxford
University).
 
Complementation of M. bovis BCG 
 

 
nat with M. tuberculosis nat.
M. tuberculosis
 
 
 
nat
 
 cloned into the 
 
Escherichia coli 
 
mycobacterial
shuttle expression vector pACE1, under control of the inducible
acetamidase promoter (15, 24), was used to complement 
 
M. bovis
 
BCG 
 

 
nat
 
. Preparation and transformation of electrocompetent
 
M. bovis
 
 BCG cells with the construct were as previously de-
scribed, with selection of transformants on 50 
 
g/ml 7H10
OADC agar-containing hygromycin. Cultures of M. bovis BCG
nat complemented with nat in pACE1 were initially maintained
in minimal medium induced with 2 mg/ml acetamide (15) and
the log phase was reached after 7 d. For experiments in which
growth characteristics were compared with other strains, the
complemented strain was grown in liquid culture in 7H9 Mid-
dlebrook medium, under which conditions the acetamide pro-
moter is known to drive basal level expression (26).
Western Blotting. We performed SDS-PAGE and Western
blotting as previously described using rabbit antiserum raised
against recombinant M. tuberculosis NAT as first antibody (21) at a
dilution of 1:10,000.
Electron Microscopy. Transmission electron microscopy (TEM)
was performed as previously described (27) and viewed on a Phil-
ips EM410 transmission electron microscope. Digital images were
taken using the Gatan multiscan Camera, model 791.
Scanning electron microscopy (SEM) was performed on poly-
lysine-coated sterile coverslips kept under PBS buffer within a
24-well plate. A drop of concentrated bacterial culture was placed
on the surface, washed three times after 1 h with PBS, and then
fixed with 3% glutaraldehyde and stained with 1% osmium te-
troxide. Critical point drying was performed after a serial wash
with 75, 85, and 95%, and twice in absolute alcohol and dry alco-
hol (kept under CuSO4). The sample was coated with platinum
vapor and observed by SEM (28).
Preparation and Analysis of Polar and Nonpolar Lipids, and Mycolic
Acids. 100 ml roller cultures were harvested at mid-exponential
phase (OD600  1.0) for each strain. The CFU values for each cul-
ture were determined separately to confirm equivalence of bio-
mass. The complex lipids and mycolic acids were extracted and the
same proportion of each culture was loaded onto thin layer chro-
matography (TLC) plates as previously described (29) to allow di-
rect visual comparison between the different strains. Identification
of components was by comparison with authenticated standards.
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Figure 1. Deleting the nat gene affects the growth of M.
bovis BCG Pasteur. (A) Growth of M. bovis BCG and M.
bovis BCG nat over a 28-d period on solid medium.
Colonies of M. bovis BCG are visible by day 21 compared
with day 28 for the nat strain (magnification, 0.2-fold).
(B) Colonies of the nat strain (KO) are smaller than the
corresponding colonies of the M. bovis BCG (WT) and
complemented strain (KO	NAT; magnification, 10-fold).
(C) When M. bovis BCG (), M. bovis BCG Pasteur nat
(), and nat complemented strains () are grown in liquid
culture (7H9 ADC and Tween 80), growth of the M. bovis
BCG nat strain is altered such that the lag phase is extended
and it is restored to the wild-type phenotype when the nat gene is reintroduced. (D) Lysates of cells harvested at mid-log phase were run on SDS-PAGE.
In each lane, lysate corresponding to 10 ml culture was loaded. Western blots were developed with specific antibodies against recombinant M. tuberculosis NAT
(reference 21) used at a 1:10,000 dilution. Lane 1, pure recombinant NAT (reference 14) as standard (C); lane 2, M. bovis BCG (WT); lanes 3 and 5, Rainbow
Molecular Weight Markers (Amersham Biosciences); lane 4, M. bovis BCG nat (KO); lane 6, M. bovis BCG nat complemented with nat (KO	NAT).
Drug Susceptibility/Sensitivity Assay. M. bovis BCG Pasteur
and nat strains were grown to mid-exponential phase (OD600 
1.0) and serially diluted using fresh liquid medium (7H9 ADC
Tween 80) and spotted at 102 cells/well in six-well plates with or
without antibiotics in 5 ml 7H10 OADC agar. Growth was ob-
served after 14 d of incubation at 37C. Mid-exponential phase
cultures were dispensed and grown in 7H9 Middlebrook me-
dium containing ADC and INH from 0 to 0.3 g/ml in 96-well
plates until cultures without INH reached the late exponential
phase (4 d). The growth rate was followed by measuring the tur-
bidity at 600 nm. The relative growth rate is expressed as a frac-
tion of the OD of the untreated wild-type cells (21).
Infectivity and Killing Assay with Macrophages. Monolayers of
the mouse macrophage cell line RAW 264.7 were grown in
RPMI 1640 with 10% FBS and plated on coverslips in multiwell
plates for 3–4 h before infection (30). Cells were washed three
times with OPTIMEM and labeled with TOPRO3 (Molecular
Probe) as previously described (31). Elicited macrophage were pre-
pared as previously described (32). M. bovis BCG Pasteur or nat
cells were harvested at mid-log phase, washed, and resuspended in
PBS. One half of the mycobacterial cells were washed and resus-
pended in OPTIMEM for infection and killing assays, and the re-
mainder were labeled with 500 g/ml FITC in NaHCO3, pH 8.5.
For opsonization, mycobacteria were incubated at 37C for 30 min
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with human serum (4:1 vol/vol), and used immediately. All solu-
tions contained 0.01% Tween 80 (Sigma-Aldrich).
Infection Assay. Bacteria were added to macrophages in a ra-
tio of 10:1 for fluorimetry, FACS® analysis, and microscopy. Cul-
tures were incubated for 2 h at 37C, washed three times in PBS,
and fixed with 4% paraformaldehyde. Cells were either stained
with ZN (Tb-color kit; Bund Deutscher Hebammen Laboratory)
for light microscopy or with TOPRO 3 for 1 h at room temper-
ature after permeabilization with 1% Triton X-100 (31) and
washing, before FACS® analysis. For FACS® and fluorimetry,
cells were recovered by scraping. Protein was measured using the
Bradford Colorimetric Assay (Sigma-Aldrich).
Killing Assay. After infection with M. bovis BCG Pasteur
and the corresponding nat mutant in 16-well plates for 2 h,
macrophage were washed thoroughly with OPTIMEM with
0.01% Tween, incubated at 37C for 2 h, 3 d, or 7 d, and then
washed with PBS with 0.01% Tween 80. After discarding the
medium, cells were lysed in distilled water at room temperature
for 10 min, and dilutions were incubated on Middlebrook 7H10
OADC agar at 37C for 28 d to determine the CFUs.
Results
Generation of M. bovis BCG Pasteur nat by Allelic Ex-
change. M. bovis BCG with an in-frame unmarked dele-
tion of the nat gene (M. bovis BCG nat) was generated us-
ing homologous recombination (25). Deletion of nat in M.
bovis BCG nat was confirmed by PCR, Southern blot-
ting, and sequencing of the vestigial nat sequence. We also
confirmed the integrity of the adjacent genes by sequencing
and PCR. The effect of deleting nat was confirmed by
NAT activity, which fell from 17.2 pmoles INH acety-
lated/min/mg protein to an undetectable level in lysates of
the M. bovis BCG nat strain. Western blotting using an
antibody that specifically recognizes NAT in cell lysates of
M. tuberculosis and M. bovis BCG (fig. 1 D) showed NAT to
be clearly present in the parental strain, but we do not de-
tect NAT protein in the lysate of M. bovis BCG nat. We
introduced the E. coli mycobacterial shuttle expression vec-
tor pACE1 (24) containing M. tuberculosis nat (14) into M.
bovis BCG nat to generate a complemented M. bovis BCG
nat strain. The level of expression of NAT in the comple-
mented strain as determined by Western blotting appears to
be similar to the wild-type strain (Fig. 1 D).
M. bovis BCG Pasteur nat Is Defective for Entry into Expo-
nential Growth Phase. The growth of M. bovis BCG is
slower when nat is deleted. This is observed both on solid
agar and in liquid cultures. On agar, colonies in which the
nat gene is deleted appear at day 28, as opposed to day 21
for the parental strain (Fig. 1 A). Growth curves in liquid
culture reveal that the strain with the nat gene deleted has
an increased lag phase (Fig. 1 C), whereas its exponential
growth rate mirrors that of the parental strain. In the com-
plemented strain, the growth is restored to that of the wild-
type, consistent with the restoration of NAT protein.
M. bovis BCG Pasteur nat Has Altered Cellular Morpholo-
gies. We observed, initially by eye, that colonies of M. bovis
BCG nat appear smaller than their parental strain counter-
parts (Fig. 1, A and B). This was confirmed by light micros-
copy; the knockout colonies appear smaller. We attempted to
quantify this morphological change using SEM and TEM.
From SEM, the individual cells of M. bovis BCG nat are sig-
nificantly (P 
 0.05) smaller (Fig. 2 C) than those of the pa-
rental cells (M. bovis BCG, total area 5.47  0.84 2; M. bovis
BCG nat, total area 3.97  0.65; average  SD, n  40).
TEM also reveals the much smoother surface of the M.
bovis BCG nat cells compared with those of the parental
strain (Fig. 2, A and B). Moreover, it is clear from the scan-
ning electron micrographs that the M. bovis BCG nat
strain lacks cord formation, which is clearly visible in the
parental cells (Fig. 2 C).
NAT Is Required for Normal Synthesis of Mycolic Acids,
Complex Lipids, and Glycolipids in M. bovis BCG Pasteur.
The effects of deleting nat on the morphology of the indi-
vidual cells suggest that the cell wall might be altered. There-
fore, we compared the lipid composition of the parental and
M. bovis BCG nat cells at the same stage of the growth cy-
cle. These comparisons show a distinct difference in the total
lipid composition of the M. bovis BCG nat strain (Fig. 3,
Figure 2. Morphology and ultrastructure of individual M. bovis BCG
Pasteur cells are modified when the nat gene is deleted. Longitudinal (A)
and transverse (B) TEM images show that the size of M. bovis BCG is
altered on deleting the nat gene. The outer cell wall (arrow), present in
M. bovis BCG, is absent in the nat strain. SEM (C) also shows the differ-
ence in size of the bacilli. Cord formation (arrow) in M. bovis BCG is
missing when the nat gene is deleted. Bar is 1 m for all frames.
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A–C). The mutant appeared to have very reduced quanti-
ties of a number of complex lipids and glycolipids, which
were identified in the wild-type as phthiocerol dimycocero-
sate (PDIM), menaquinone (MK), glucose monomycolate
(GMM), and trehalose dimycolate or cord factor (CF) using
two-dimensional TLC (Fig. 3, A and B). We further ana-
lyzed the delipidated cell walls to compare bound mycolic
acids (Fig. 3 C). There appears to be very little mycolic acid
present within M. bovis BCG nat, either in extractable lip-
ids or bound to the cell wall (Fig. 3, A and B). However, the
presence of normal mycolic acid production and complex
lipid patterns is restored on complementation with M. tuber-
culosis nat. The cultures used for mycolic acid analyses were
plated out to ensure no contamination by nonmycobacterial
organisms had occurred. It is these cultures that are illustrated
in Fig. 1 A. We see no visible difference between the nat
and parental strain among other extractable components of
the cell wall, particularly the phospholipids (Fig. 3 E), al-
though the amount of extractable fatty acid is slightly dimin-
ished in the M. bovis BCG nat strain (Fig. 3 D).
M. bovis BCG Pasteur nat Is More Sensitive toward Intra-
cellular Killing within Macrophages. When unopsonized M.
bovis BCG or M. bovis BCG nat bacilli are incubated with
the mouse macrophage cell line (RAW 264.7), we ob-
served no difference in cellular uptake (Fig. 4, A and B)
into macrophages. Experiments with elicited macrophages
showed the same results. However, intracellular M. bovis
BCG nat bacilli are killed after 3 d, whereas the wild-type
strain is not (Fig. 4 C). Opsonization does not appear to al-
ter the marked difference in intracellular killing, although
after opsonization there is a fivefold increase in the number
of M. bovis BCG cells taken up for both the M. bovis BCG
and M. bovis BCG nat bacilli.
M. bovis BCG Pasteur nat Is More Susceptible to Antibiot-
ics. We reasoned that the change in the composition of
the cell wall of M. bovis BCG nat strain would result in
greater accessibility of antibiotics. We show this is the case
using the antibiotics hygromycin and gentamycin. These
antibiotics are approximately one order of magnitude more
effective in the strains with the nat gene deleted (Table I).
Studies with  lactam antibiotics show that deletion of nat
increases susceptibility only marginally.
The M. bovis BCG nat strain is twofold more sensitive
to INH than the parental strain of M. bovis BCG Pasteur
(Fig. 5). The growth of the nat strain was inhibited at
a twofold lower INH concentration than the wild-
type, whereas the complemented strain was indistinguish-
able from the wild-type in its INH sensitivity.
Figure 3. Total lipid and mycolate profile of M. bovis BCG Pasteur is changed when
the nat gene is deleted. Analysis of total lipids by two-dimensional TLC shows that tri-
acyl glycerol (TAG), MK, and PDIM (A), as well as CF and GMM (B), are present in M.
bovis BCG (WT), but missing from the corresponding nat BCG strain (NAT KO). All
of these complex lipids are restored by complementation with nat (KO	NAT). Separation
of mycolates from the same dry weight of delipidated cells by one-dimensional TLC from
WT, NATKO, and KO	NAT, shows that the synthesis of mycolate in WT is perturbed
by deletion of the nat gene and is fully restored when the M. tuberculosis nat gene is intro-
duced (C). Analyses of fatty acids and multi-acetylated trehaloses (D) and of phospholipids
(E) shows very little change between the M. bovis BCG (WT) and nat BCG strain
(NAT KO). Analyses were performed using the same biomass of the parental and mutant
cultures. TAG, tri-acyl glycerol; MK, menaquinone; PDIM, pthiocerol dimycocerosate;
CF, cord factor; GMM, glucose monomycolate; MAMES, mycolic acid methyl esters;
FAMES, fatty acid methyl esters; MAT, multi-acylated trehaloses; F, Fatty acids; PIMs,
phosphatidyl-inositol mannosides; PE, phosphatidyl ethanolamines.
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Discussion
To investigate the endogenous role of NAT in myco-
bacteria, we deleted the nat gene from M. bovis BCG Pas-
teur and observed phenotypic changes on (a) growth, (b)
ultrastructure and cell morphology, (c) cell wall lipid com-
position, and (d) intracellular killing of M. bovis BCG Pas-
teur by mouse macrophages. Deletion of nat affects growth
Figure 4. Deleting the nat gene affects the intracellular killing of M.
bovis BCG Pasteur in macrophages. Infection of mouse macrophage cell
line RAW showing that the uptake of M. bovis BCG (WT) and M. bovis
BCG nat (NATKO) into RAW cells is the same, and there is an equal
increase in uptake for both M. bovis BCG and the corresponding nat
mutant after opsonization (OPS). (A) Fluorimetric assay. (B) FACS®.
Upper right quadrants of B show RAW cells that have taken up FITC-
BCG. (C) Intracellular killing assay. The mouse macrophage cell line
RAW was infected and samples were taken at the times indicated, plated
on agar, and CFUs were counted, showing that M. bovis BCG with and
without opsonization can survive and is able to grow within macrophages
after 7 d, whereas M. bovis BCG nat with and without opsonization are
killed between 2 and 72 h after infection. , wild-type strain; , nat
strain. Solid lines are opsonized and dotted lines are unopsonized.
Table I. Knocking out nat Affects Sensitivity of M. bovis BCG Pasteur to a Variety of Antibiotics
Ampicillin Cloxacillin Carbenicillin Gentamycin Hygromycin
Concentration WT KO WT KO WT KO WT KO WT KO
Control 			 			 			 			 			 			 			 			 			 			
5 g/ml 			 			 			 			 			 			 			 	 			 	
10 g/ml 			 			 			 			 			 			 			  			 
20 g/ml 			 		 			 			 			 			 	  			 
30 g/ml 			 		 			 		 			 			 	  	 
40 g/ml 		  		  			 	 	  	 
50 g/ml     	  	   
M. bovis BCG (WT) and M. bovis BCG with nat deleted (KO) were plated at 102 cells/well on 7H10 OADC agar-containing antibiotics as indicated,
in six-well plates. Cell growth was recorded after 14 d at 37C. Good growth (			), poor growth (	), and no visible growth () are indicated.
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of M. bovis BCG Pasteur on plates and retards the growth
in liquid culture by increasing the duration of the lag phase.
It has been demonstrated that the nat gene in certain clini-
cal isolates of M. tuberculosis (from amongst a related group
of isolates that share a particular IS1160 genotype and are
known as family 28) harbor a mutation (33) in the nat gene
that renders the NAT protein less active (14). Observations
on the growth of these clinical isolates have repeatedly
demonstrated that they grow exceptionally slowly on agar
and in liquid culture. Although the members of family 28
harbor other mutations, these data indicate that NAT activ-
ity may influence growth of M. tuberculosis as well as of M.
bovis BCG. We have recently generated a strain of M. tuber-
culosis H37Rv in which the nat gene has been deleted and
have observed that the effect on colony morphology mir-
rors our results on the effect of deleting the nat gene in M.
bovis BCG.
The ultrastructure of M. bovis BCG Pasteur is affected
when nat is deleted and the cell wall is greatly diminished as
observed in TEM. Biochemical analysis of the cell wall lip-
ids clearly shows that the M. bovis BCG nat mutant has
less mycolic acids and other mycolic acid derivatives like
GMM and CF as well as other complex lipids, such as
PDIM and MK. Consistent with the lack of CF, we have
found cord formation is absent in M. bovis BCG nat mu-
tant from ultrastructural analysis by SEM. Studies of these
cell wall components of mycobacteria are also consistent
with the biochemical findings. PDIM, which is found only
in pathogenic mycobacteria, is required for growth in the
lungs of mice and is associated with virulence (34). Myco-
bacterial GMM is a target of the human immune response
to mycobacteria (35) and CF is able to stimulate innate,
early adaptive, and both humoral and cellular adaptive im-
munity (36), and induces prolonged mycobacterial survival
(37). MK is a component of the respiratory chain of myco-
bacteria. The effects of environmental conditions on the
structure and function of the respiratory chain are begin-
ning to be understood (38). MK appears to be essential (39)
and its level in the nat strain might be below the level of
detection in the experiments presented here. We have
found that the changes in mycolates and associated com-
plex lipids from the cell wall is associated with increased
sensitivity of mycobacteria to intracellular killing by mouse
macrophages, regardless of opsonization. Dilapidation of
M. tuberculosis similarly affects survival in bone marrow–
derived macrophages (40). It is not certain how a decrease
in the content of complex lipids contributes to the ob-
served phenotype or whether the pattern of lipid changes is
a primary defect or a secondary effect as a result of interfer-
ence of normal mycolic acid synthesis, for example through
shedding. It is possible that NAT has a role in maintaining
homeostasis of acetyl-CoA, a central metabolite in lipid
synthesis and hence its lack would affect different synthetic
pathways. In this context, it has been observed that a trun-
cation mutant of NAT that catalyses hydrolysis of acetyl-
CoA is toxic to E. coli (41). The effects of deleting the nat
gene on lipid biosynthesis in M. bovis BCG is not universal.
Although mycolic acids and their methyl esters are greatly
affected, fatty acids are only diminished slightly. These data
suggest that NAT may play a role in extension of the chain
length of fatty acids before esterification. The biochemical
mechanisms of extension of fatty acyl chains is dependent
on chain length (11) and in this context it might be signifi-
cant that in preliminary experiments, we have found NAT
associated with the cell membrane fraction under certain
growth conditions.
INH is a substrate of NAT and hence INH is indisput-
ably a NAT ligand (42). We have obtained a three-dimen-
sional crystallographic structure of NAT with INH bound
(unpublished data). The precise target of INH in mycobac-
teria leading to inhibition of mycolic acid synthesis has
been the subject of continued debate (43, 44). Studies that
we have performed with pure proteins suggest that KatG
and NAT compete for INH, supporting the interpretation
that NAT acts to control the amount of active INH avail-
able and hence modulates INH sensitivity. The interest in
mycolic acids stems from their exclusivity to mycobacteria,
making these biosynthetic pathways obvious targets for an-
timycobacterial drugs. Routes leading to mycolic acid bio-
synthesis are not fully established (45, 46), although studies
with a viable strain of Mycobacterium smegmatis defective in
mycolate biosynthesis (5) as well as Mycobacterium aurum
treated with INH (47) suggest that mycobacterial cells can
survive with severely reduced mycolic acid content of the
cell wall. A reduction in mycolates makes these organisms
more permeable and is in agreement with the results pre-
sented here on increased sensitivity to antibiotics in the
nat strain of M. bovis BCG Pasteur.
Although INH is a substrate for M. tuberculosis NAT
(14), NAT is unlikely to be an additional target for INH.
Nevertheless, a reduction in mycolic acid as well as de-
Figure 5. Deleting nat affects sensitivity of M. bovis BCG Pasteur to
INH. Mid-log phase cultures of M. bovis BCG (), M. bovis BCG nat
(), and M. bovis BCG nat complemented with nat () were grown in
the presence of differing concentrations of INH. The growth was deter-
mined after 4 d and is expressed relative to the corresponding strain cul-
tured without INH. Mean values of three determinations are shown and
the SD is within the symbol.
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creasing the effectiveness of the cell wall as a barrier to pro-
tein extrusion (47), mirrors the ultrastructural effects we
have observed on deleting the nat gene. These data, to-
gether with the increased intracellular killing by macro-
phages of M. bovis BCG Pasteur nat, indicate that specifi-
cally targeting the NAT protein may serve both to increase
the effectiveness of combination therapy by an order of
magnitude and shorten the treatment time for active infec-
tion through inhibiting cell wall biosynthesis.
To target the NAT protein, we have developed a high
throughput assay (48) and are using this with combinatorial
chemistry and modeling on the NAT 3-D structure (42) to
generate compounds to test both on mycobacterial growth
in culture and mycobacterial killing in macrophages.
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